We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
NovaTec Immundiagnostica GmbH

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer’s EUROIMMUN Launches Anti-SARS-CoV-2 QuantiVac ELISA (IgG) to Measure IgG Antibodies Against SARS-CoV-2 S1 Antigen

By LabMedica International staff writers
Posted on 10 Nov 2020
Print article
Image: Anti-SARS-CoV-2 ELISA (IgG) (Photo courtesy of EUROIMMUN)
Image: Anti-SARS-CoV-2 ELISA (IgG) (Photo courtesy of EUROIMMUN)
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.

The quantitative test kit applies a recombinant S1 subunit of the SARS-CoV-2 spike protein, enabling detection of IgG antibodies. These antibodies have been the focus of vaccine development programs as well as discussions about possible immunity in previously infected individuals. With the new ELISA assay, EUROIMMUN is providing a product to support careful evaluation of an important antibody subgroup enabling standard curve-based quantification of the anti-S1 IgG antibody concentration.

The assay is available for countries accepting the CE mark, and the company plans to file a request for the product with the US Food and Drug Administration for Emergency Use Authorization (EUA). The QuantiVac ELISA assay adds to the company’s broad product portfolio of COVID-19 diagnostics and is based on the CE-marked and FDA EUA-approved semi quantitative/qualitative Anti-SARS-CoV-2 ELISA (IgG).

EUROIMMUN has increased its ELISA production for COVID-19 diagnostics to more than three million tests per week and can supply large numbers of dried blood spot collection sets for upcoming seroprevalence and vaccination development studies. Large international reference laboratories have implemented EUROIMMUN SARS-CoV-2 assays, and the tests are being applied in an increasing number of epidemiological studies worldwide.

“The global research and medical community is focused on having an effective SARS-CoV-2 vaccine available as soon as possible, but to do so, it’s clear that the quantitative measurement of antibodies in clinical studies will play a huge part,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN. “The EUROIMMUN assays, especially the S1-based tests, are important tools for pharmaceutical laboratories conducting clinical trials. Our assays can help to identify individuals who have been exposed to SARS-CoV-2 and may play a critical role in accurate evaluation of antibody status before and after infection, in antibody therapies or in vaccination programs.”



Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.